Alvotech is trading 16.3% up at ISK 628 after investors responded to its Lotus Pharmaceutical licensing agreement.
- It covers proposed durvalumab and emicizumab biosimilars, with up to approximately $150 million in upfront and milestone payments, plus product-supply revenue.
- The August 24 surge was also attributed to the first-half 2026 earnings release and progress resolving FDA manufacturing issues, including application resubmissions.
- Approximately 3.16 million shares changed hands; the move appeared company-specific amid a modestly firmer broader market.